ライフサイエンスコーパス: A1c

1 A1c was considered controlled if individuals were aged <

2 A1c was lower in ATG/G-CSF-treated subjects at the 6-mon

3 years; body mass index = 29 +/- 1 kg/m(2) ; A1c = 5.7 +/- 0.1%) were studied on two occasions, with

4 e importance of glycosylated hemoglobin A1c (A1c) control as part of comprehensive risk factor manage

5 ar physical activity, dietary adherence, and A1c <7%.

6 actors, particularly lifestyle behaviors and A1c, were associated with improved survival.

7 tivity, diet adherence, body mass index, and A1c.

8 n fully adjusted models (for glycohemoglobin A1c, standardized B=-0.10 [-0.15 to -0.05], P<0.001 and

9 In addition, higher glycohemoglobin A1c and fasting plasma glucose were associated with lowe

10 t 2 years, defined as a glycated haemaglobin A1c (HbA1c) concentration of 6.5% or less (</=47.5 mmol/

11 Haemoglobin A1c (HbA1c) is a significant glycaemic marker for diabet

12 nts, including disease duration, haemoglobin A1c (HbA1c) levels and urine albumin creatinine ratio.

13 including serum fasting glucose, haemoglobin A1c levels, creatinine levels, and the urinary albumin-t

14 and centrally confirmed glycated haemoglobin A1c (HbA(1c)) of 48-58 mmol/mol (6.5-7.5%) and a body-ma

15 d type 2 diabetes, mean glycated haemoglobin A1c (HbA1c) concentration of 67 mmol/mol (8.3%), and ris

16 outcome was a change in glycated haemoglobin A1c (HbA1c) from baseline to week 26, with a 0.4% non-in

17 r with type 2 diabetes, glycated haemoglobin A1c (HbA1c) of 7.0% or more, receiving metformin, sulfon

18 ith type 2 diabetes and glycated haemoglobin A1c (HbA1c) of 7.0-9.5% on stable metformin were randoml

19 Mean glycated haemoglobin A1c concentrations were also higher in the fasting and 2

20 ile, glucose tolerance, glycated haemoglobin A1c, salivary cortisol, sitting height, and head circumf

21 quately controlled (glycosylated haemoglobin A1c [HbA1c] >/=7.0% to </=10.0%) patients with type 2 di

22 ol misuse, well-being, change in haemoglobin A1c (HbA1c), and smoking cessation.

23 lucose, 2-h glucose and insulin, haemoglobin A1c, high-density lipoprotein or blood pressure.

24 ting hyperglycaemia and lowering haemoglobin A1c levels than Exendin-4, suggesting that GLP-1R G-prot

25 ent of all recommended levels of haemoglobin A1c (HbA1c), BP, and cholesterol; risky prescribing leve

26 +/- 0.043), ferritin (-0.212 +/- 0.075), Hb A1c (-0.052 +/- 0.015), and fasting insulin (-0.119 +/-

27 tin, fasting insulin, and hemoglobin A1c (Hb A1c).

28 lasma CRP, ferritin, fasting insulin, and Hb A1c and lower adiponectin after adjustment for demograph

29 r regression models adjusted for baseline Hb A1c, sociodemographic variables, diabetes-related variab

30 cant proportion of associations with CRP, Hb A1c, and fasting insulin (P-contribution </= 0.02 for al

31 +/- 0.5 mg/dL), PI (-1.52 +/- 0.6 mg/dL), Hb A1c (-0.02 +/- 0.0%), and HOMA-IR (-0.04 +/- 0.0) after

32 dL for PG, and -0.01% (-0.02%, 0.00%) for Hb A1c.

33 Improved glycated hemoglobin (Hb A1c) delays the progression of microvascular and macrova

34 stload insulin (PI), glycated hemoglobin (Hb A1c), and homeostasis model assessment of insulin resist

35 A total of 9.3% of participants had poor Hb A1c (value >/=9.5%) at baseline, which increased to 18.3

36 001, P = 0.003) associated with follow-up Hb A1c after adjustment for confounders.

37 ntly negatively associated with follow-up Hb A1c after adjustment for confounders.

38 utritional factors may be associated with Hb A1c during early stages of disease progression in youth

39 associations of nutritional factors with Hb A1c in youth with T1D.

40 d for direct detection of hemoglobin A1c (Hb(A1c)), a potent biomarker for diabetes diagnosis and pro

41 The polymer allowed Hb(A1c) selectively bound to its surface via forming the ci

42 edox current of PAPBA decreased due to an Hb(A1c) binding-induced ion flux blocking mechanism, which

43 method for developing an electrochemical Hb(A1c) biosensor and can be extended to other label-free,

44 s a linear dependence on the logarithm of Hb(A1c) concentration ranging from 0.975 to 156 muM.

45 Voltammetric analyses showed that Hb(A1c) binding decreased the redox current of PAPBA; howev

46 The Hb(A1c) assay also showed high selectivity against ascorbic

47 Assay with Hb(A1c) by differential pulse voltammetry (DPV) indicates t

48 outcomes included changes in hemoglobin (Hb) A1c (primary outcome), fasting plasma glucose (FPG), ser

49 Hemoglobin A1c (HbA1c) and fasting blood glucose levels (FBGLs) wer

50 Hemoglobin A1c (HbA1c) is the standard measure to monitor glucose c

51 Hemoglobin A1c (HbA1c) is widely used to diagnose diabetes and asse

52 Hemoglobin A1c (HbA1c) levels were also recorded.

53 Hemoglobin A1c (HbA1c) levels were recorded.

54 Hemoglobin A1c (HbA1c) reflects past glucose concentrations, but th

55 Hemoglobin A1c goals are less than 6.5% at conception and less than

56 Hemoglobin A1c level was not associated with any MR imaging measure

57 Hemoglobin A1c levels were ordered at all ICU admissions from March

58 Hemoglobin A1c stratified by the presence or absence of SCT was the

59 Hemoglobin A1c thresholds of 5.7% and 6.5% were the least effective

60 Prediabetes (glucose based, 4.0%; hemoglobin A1c based, 15.4%) and diabetes (glucose based, 3.0%; hem

61 nd diabetes (glucose based, 3.0%; hemoglobin A1c based, 2.9%) were less frequent.

62 dL vs 8 +/- 17 mg/dL [P < .001]), hemoglobin A1c levels (26 weeks: 0.1 +/- 0.3% vs 0.3 +/- 0.4% [P <

63 rol (194 vs 186 mg/dL; P = .027), hemoglobin A1c (5.9% vs 5.7%; P = .003), and body mass index (30.8

64 abetes was defined as follows: 1) hemoglobin A1c values ranging from 5.7% to 6.4% or 2) fasting plasm

65 tients (mean age, 58 yr [SD, 10], hemoglobin A1c 36.8 mmol/mol [4.9 mmol/mol]) with 35 attending the

66 l [CI], 1.7%-3.3% per 5 kg/m(2)), hemoglobin A1c (HbA1c) level (2.2%; 95% CI, 1.0%-3.5% per 1%), and

67 ration rate, mL/min per 1.73m(2); hemoglobin A1c, 8.0%; 62.9% men; diabetes mellitus duration, 14.8 y

68 [OR], 0.77 [95% CI, 0.65-0.91]); hemoglobin A1c assessment (OR, 0.79 [95% CI, 0.66-0.94]); beta-bloc

69 e level of 200 mg/dL or higher, a hemoglobin A1c (HbA1c) of 6.5% or higher, or diabetes treatment.

70 ears, the harms associated with a hemoglobin A1c (HbA1c) target lower than 7.5% or higher than 9% are

71 Prediabetes was defined as a hemoglobin A1c level of 5.7% to 6.4%, an FPG level of 100 mg/dL to

72 ot previously diagnosed, by (1) a hemoglobin A1c level of 6.5% or greater or a fasting plasma glucose

73 Participants with a hemoglobin A1c level of 7% or greater, diabetes, or other chronic d

74 t (55% effectiveness; $498), or a hemoglobin A1c threshold of 5.5% (45% effectiveness; $763).

75 ectively; 26.7% met combined ABC (hemoglobin A1c, BP, and LDL cholesterol) targets, and 21.3% met com

76 ticipants with diabetes achieving hemoglobin A1c levels less than 6.5% or fasting plasma glucose valu

77 2DM) may fail to achieve adequate hemoglobin A1c (HbA1c) control despite metformin-sulfonylurea (Met-

78 After adjustment for sex, age, hemoglobin A1c level, and retinopathy level at DCCT baseline, the f

79 esented 41.0% of patients with an hemoglobin A1c > 6.5% and 9.3% of all ICU patients.

80 A total of 15,737 patients had an hemoglobin A1c and medical record evaluable for the history of diab

81 In a meta-analysis, hemoglobin A1c level decreased by 0.4% (95% CI, 0.1% to 0.7%) (n =

82 >/=7.0 mmol/L [>/=126 mg/dL]) and hemoglobin A1c (>/=6.5%) in persons without diagnosed diabetes.

83 adiponectin, fasting insulin, and hemoglobin A1c (Hb A1c).

84 n levels, insulin resistance, and hemoglobin A1c (HbA1c) levels in first-episode antipsychotic-naive

85 mmol/L or less (</=225 mg/dL) and hemoglobin A1c (HbA1c) levels of 7.0% to 9.5% who were treated for

86 llected using a questionnaire and hemoglobin A1c (HbA1c) levels were measured.

87 Fasting blood glucose (FBG) and hemoglobin A1c (HbA1c) levels were recorded.

88 Fasting blood glucose (FBG) and hemoglobin A1c (HbA1c) levels, periodontal parameters (plaque index

89 ividuals with type 1 diabetes and hemoglobin A1c (HbA1c) of at least 7.5% (58 mmol/mol) treated with

90 of at least 10 (range, 0-27); and hemoglobin A1c (HbA1c) of at least 8%, systolic blood pressure (SBP

91 by height in meters squared) and hemoglobin A1c (HbA1c) was greater than or equal to 6.5%.

92 glucose, insulin, proinsulin and hemoglobin A1c (HbA1c).

93 rence, lipids, serum glucose, and hemoglobin A1c (HbA1c).

94 ween the continuous DNN score and hemoglobin A1c (P <= 0.001) among those with hemoglobin A1c data.

95 mg/dL; 95% CI=-39.2 to -1.3), and hemoglobin A1c level (-0.07%; 95% CI=-0.14 to -0.004).

96 /min/1.73 m2 [IQR, 51.6-58.2] and hemoglobin A1c level of 6.6% [IQR, 6.1%-7.2%] at cohort entry).

97 ian of 14 months (IQR, 5-30), and hemoglobin A1c level was 8.1% (IQR, 7.2%-9.9%).

98 (SD) age was 47.3 (6.4) years and hemoglobin A1c level, 7.9% (2.0%).

99 blood pressure, cholesterol, and hemoglobin A1c levels and treatment and control rates in 1154 self-

100 ed with fasting blood glucose and hemoglobin A1c levels in men with T2DM, but not women with T2DM.

101 triglyceride, blood glucose, and hemoglobin A1c levels sharply decreased during the first 2 years af

102 llected using a questionnaire and hemoglobin A1c levels were measured.

103 or CVD, inflammatory markers, and hemoglobin A1c levels).

104 ction Questionnaire 25 scores and hemoglobin A1c levels.

105 er measure): eye examinations and hemoglobin A1c testing for patients with diabetes, chlamydia screen

106 ficacy, medication adherence, and hemoglobin A1c values.

107 hypertension, hyperlipidemia, and hemoglobin A1c were collected.

108 ons in fasting glucose levels and hemoglobin A1c were greater after distal gastric bypass.

109 P, CCT, FBS, fasting insulin, and hemoglobin A1c were null.

110 tal body fat mass, VAT, SSAT, and hemoglobin A1c were reduced comparably in both intervention groups.

111 Associations of BP and hemoglobin A1c with change in eGFR were strongest for eGFR(Cys) and

112 ssment of insulin resistance, and hemoglobin A1c) compared with fast ethanol metabolizers (persons ho

113 ype 2 diabetes, hypertension, and hemoglobin A1c, fasting insulin, homeostatic model assessment of in

114 olesterol, smoking cessation, and hemoglobin A1c.

115 We defined diabetes as hemoglobin A1c >=6.5% or self-report and CKD by urinary albumin/cre

116 Unfortunately, tests such as hemoglobin A1c (HbA1c)/fasting plasma glucose (FPG) alone fail to d

117 Diabetes was defined as hemoglobin A1c greater than 6.5% or use of glucose-lowering medicat

118 sures of diabetes status (such as hemoglobin A1c levels), and quality of life.

119 osity, stable adiposity, baseline hemoglobin A1c (HbA1c) > 5.05%, HbA1c < 4.92%] and assayed using GC

120 The association of baseline hemoglobin A1c (HbA1c) at the time of percutaneous coronary interve

121 tus and glycemic status (baseline hemoglobin A1c [HbA1c]: < 6.0% [< 42 mmol/mol], 6.0%-6.4% [42-47 mm

122 48% were female, average baseline hemoglobin A1c level was 8.7%, and 27% were prescribed insulin.

123 sion making, glycemic biomarkers, hemoglobin A1c target ranges, individualized treatment plans, outpa

124 ng plasma glucose (FPG) and blood hemoglobin A1c (HbA1c) than individuals of other genotypes.

125 ignificantly associated with BMI, hemoglobin A1c, systolic blood pressure, total cholesterol, LDL cho

126 nd control of diabetes defined by hemoglobin A1c (HbA1c) levels are important for health care policy

127 t of glycemic status evaluated by hemoglobin A1c (HbA1c) on the risk of thromboembolism among patient

128 rmacodynamic effects, assessed by hemoglobin A1c (HbA1c), body weight, and blood lipid concentrations

129 eadmission glycemia, reflected by hemoglobin A1c obtained at the onset of ICU admission, has a signif

130 Patients were stratified by hemoglobin A1c: less than 6.5.(n = 4,406), 6.5-7.9% (n = 711), and

131 -density lipoprotein cholesterol, hemoglobin A1c, albuminuria, glomerular filtration rate, smoking, a

132 od pressure, waist circumference, hemoglobin A1c (HbA1c), insulin resistance, triglycerides, HDL chol

133 chieve diabetes mellitus control (hemoglobin A1c <=7% in 51.3% versus 54.3%; P<0.001 for all comparis

134 haracteristics, glycemic control (hemoglobin A1c [HbA1c]), and presence of diabetic complications wer

135 independent of diabetes control (hemoglobin A1c, blood pressure, and lipid levels), presenting visua

136 perglycemia, and glucose control; hemoglobin A1c (HbA1c); and cognition and patient-reported outcomes

137 Current hemoglobin A1c level was not associated with either receiving an in

138 Baseline descriptive data, hemoglobin A1c (%) level, time since diagnosis of T1DM (months), an

139 and uncontrolled known diabetes (hemoglobin A1c > 6.5%, with documented history of diabetes).

140 rized as having unknown diabetes (hemoglobin A1c > 6.5%, without history of diabetes), no diabetes (h

141 etes), controlled known diabetes (hemoglobin A1c < 6.5%, with documented history of diabetes), and un

142 istory of diabetes), no diabetes (hemoglobin A1c < 6.5%, without history of diabetes), controlled kno

143 mally controlled type 1 diabetes (hemoglobin A1c [HbA1c] >8.0%) were recruited from the Diabetes Cent

144 participants developed diabetes (hemoglobin A1c level >/=6.5%) during the trial: 7 in the high-fiber

145 90 mm Hg), uncontrolled diabetes (hemoglobin A1c level >8%), obesity (body mass index >30), and depre

146 100 by age, duration of diabetes, hemoglobin A1c (HbA1c), body mass index (BMI), best-corrected visua

147 mong adults with type 2 diabetes, hemoglobin A1c of 6.5% to 10.0%, high CV risk (history of vascular

148 cose level of at least 200 mg/dL, hemoglobin A1c concentration of at least 6.5% of total hemoglobin,

149 diabetes type, diabetes duration, hemoglobin A1c (HbA1c) levels, and baseline DR severity.

150 We investigated whether elevated hemoglobin A1c (HbA1c) is associated with the development of pancre

151 duration of diabetes and elevated hemoglobin A1c (HbA1c) with risk of stroke among diabetic patients

152 er medical history or an elevated hemoglobin A1c in the ICU.

153 agnosed adults have less elevated hemoglobin A1c levels, less lipid treatment and worse control, and

154 r age, gender, race or ethnicity, hemoglobin A1c, duration of diabetes, high-density lipoprotein leve

155 ease monitoring (eye examination, hemoglobin A1c testing, and low-density lipoprotein cholesterol tes

156 ease monitoring (eye examination, hemoglobin A1c testing, and low-density lipoprotein cholesterol tes

157 tes and established risk factors (hemoglobin A1c level, body mass index, waist-height ratio, and mean

158 6) years for age, 7.8% (1.9%) for hemoglobin A1c level, and 171.3 (72.5) mg/dL for fasting plasma glu

159 Blood samples were assessed for hemoglobin A1c, fasting blood glucose, and serum lipids.

160 200 mg/dl (11.1 mmol/l), glycated hemoglobin A1c (HbA1c) >6.5%, self-reported physician-diagnosed dia

161 CIs) were calculated for glycated hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), total cholest

162 ur CG [2-hCG] level, and glycated hemoglobin A1c [HbA1c] level) at enrollment, and cases were tested

163 thnicity, net worth, and glycated hemoglobin A1c fraction (HbA1c).

164 or duration of diabetes, glycated hemoglobin A1c level, and other factors, we found that neither the

165 Glycated hemoglobin A1c levels improved to 7.0% [6.4%-7.5%] in the DJBL grou

166 The mean (SD) glycated hemoglobin A1c of the 50 patients (26 men and 24 women; 35 Chinese;

167 waist circumference with glycated hemoglobin A1c reduction is likely due to selection bias.

168 significant predictor of glycated hemoglobin A1c reduction was waist circumference, lower baseline wa

169 , whereas guidelines for glycated hemoglobin A1c testing for type 2 diabetes mellitus could be improv

170 by assessment of HbA1c (glycated hemoglobin A1c) levels, which poorly reflects direct glucose variat

171 Weight, BMI, glycated hemoglobin A1c, fasting glucose, and insulin were abstracted by 2 i

172 n histories of patients' glycated hemoglobin A1c, hypertension, hyperlipidemia, smoking, and renal im

173 rating scale), level of glycated hemoglobin A1c, level of C-reactive protein, body mass index, and p

174 The importance of glycosylated hemoglobin A1c (A1c) control as part of comprehensive risk factor m

175 Research targeting glycosylated hemoglobin A1c (HbA1c) to <6.5% to prevent coronary heart disease (

176 Elevated levels of glycosylated hemoglobin A1c (OR, 1.47; 95% CI, 1.26-1.71 for each 1%; P < .001)

177 , diabetes duration, glycosylated hemoglobin A1c, and fasting C-peptide.

178 teopontin, and serum glycosylated hemoglobin A1c, insulin, and glucose were analyzed in 220 participa

179 f diabetes mellitus, glycosylated hemoglobin A1c, statin use, and end-stage renal disease.

180 G) level of 126 mg/dL or greater (hemoglobin A1c or FPG definition) or (2) additionally including 2-h

181 G) level of 200 mg/dL or greater (hemoglobin A1c, FPG, or 2-hour PG definition).

182 ly injections of insulin, and had hemoglobin A1c (HbA1c) levels of 7.5% to 9.9% (mean, 8.5%).

183 daily insulin injections and had hemoglobin A1c (HbA1c) levels of 7.5% to 9.9%.

184 cases had a glycated hemoglobin (hemoglobin A1c) test as one of the pair of events identifying diabe

185 res-blood pressure <140/90 mm Hg, hemoglobin A1c <=9% in diabetic patients, statin use, and antiplate

186 athy group and patients with high hemoglobin A1c (HbA1c) values (>/= 6.5%, >/= 48 mmol/mol) exerted s

187 high depression ratings and high hemoglobin A1c levels had the lowest mean FA values in the right AL

188 e exists as to whether the higher hemoglobin A1c (HbA1c) levels observed in black persons than in whi

189 Patients with higher hemoglobin A1c levels (OR, 1.19 per unit change; 95% CI, 1.13-1.25

190 At admission to ICU, hemoglobin A1c was measured in eligible patients.

191 Insulin can help achieve ideal hemoglobin A1c goals for patients with type 2 diabetes.

192 Primary outcome was change in hemoglobin A1c (HbA1c) from baseline to 12-month follow-up, and equ

193 e primary end point was change in hemoglobin A1c (HbA1c) from baseline to week 26.

194 er metformin-induced reduction in hemoglobin A1c (HbA1c) in 10,577 participants of European ancestry.

195 ssociated with acute decreases in hemoglobin A1c (HbA1c).

196 was 40% higher per 1% increase in hemoglobin A1c (OR = 1.4, 95% CI 1.1-1.6), was 30% higher per 5 yea

197 ic control (>/= 0.4% reduction in hemoglobin A1c [HbA1c]), whereas most diabetes self-management educ

198 econd example concerns changes in hemoglobin A1c in a nonrandomized study.

199 Change in hemoglobin A1c level (primary outcome) and safety and efficacy meas

200 ulted in a remarkable decrease in hemoglobin A1c levels (7.4+/-1.9 pre-LVAD versus 6.0+/-1.5 and 6.3+

201 group and had a small increase in hemoglobin A1c levels (between-group difference, -0.2%; 95% CI, -0.

202 e, 0.9-1.43 point improvements in hemoglobin A1c levels) during 1 to 2 years of follow-up than nonsur

203 was associated with a decrease in hemoglobin A1c of approximately 1.0%.

204 n 2006 and 2010, but increases in hemoglobin A1c testing may have contributed to rising diabetes inci

205 Reductions in hemoglobin A1c values were similar across monotherapies and metform

206 tic individuals, a 1% increase in hemoglobin A1c was associated with greater AD signature hypometabol

207 greater weight loss, reduction in hemoglobin A1c, and use of antidiabetic medications, and very impor

208 nificant effects on the change in hemoglobin A1c, glucose, and insulin levels.

209 ated clinical measures, including hemoglobin A1c level and vascular risk factors, and neuropsychologi

210 Increasing hemoglobin A1c levels were associated with significant increases in

211 .6%, and 80.6% met individualized hemoglobin A1c, blood pressure (BP <140/80 mmHg), lipid (low-densit

212 t of insulin resistance, insulin, hemoglobin A1c, and low high-density lipoprotein had significant sh

213 t of insulin resistance, insulin, hemoglobin A1c, and low high-density lipoprotein had significant sh

214 >/= 30 consecutive days, and (iv) hemoglobin A1c >/= 6.5%.

215 , medications, cholesterol level, hemoglobin A1c level, creatinine level, blood pressure, body mass i

216 index, C-reactive protein level, hemoglobin A1c level, phosphorus level, troponin T level, log N-ter

217 controlled blood glucose levels (hemoglobin A1c (HbA1c) levels of >7) also had intracellular HA, whe

218 ng fasting plasma glucose levels, hemoglobin A1c levels, and duration of diabetes.

219 peptide (in nanomoles per liter), hemoglobin A1c (as a percentage) and insulin dose (U/kg per day) as

220 Lower hemoglobin A1c and BP and regression to AER<300 mg/d were associate

221 sociated with significantly lower hemoglobin A1c levels (beta = -0.37; 95% CI, -0.72 to -0.01) and a

222 Lower hemoglobin A1c levels (P < 0.01), having insurance (P = 0.01), and

223 ry outcome was the change in mean hemoglobin A1c (HbA1c) levels estimated over three 12-month periods

224 range, 0.1-16.2 years) and a mean hemoglobin A1c (HbA1c) of 8.6 (range, 5->/=14).

225 Mean hemoglobin A1c for the population was 7.9+/-1.8%.

226 Mean hemoglobin A1c increased from baseline during the study: +0.7 mmol/

227 Although mean hemoglobin A1c levels between groups were equivalent, the EW versus

228 quartile range 25.5-35.3), median hemoglobin A1c was 6.8 (interquartile range 6.2-7.8), and 34% had e

229 patients with diabetes mellitus (hemoglobin A1c, 10+/-2%) demonstrated reduced overall cell numbers

230 7.0%, 57.9%, 36.0%, and 77.9% met hemoglobin A1c, BP, lipid, and nonsmoking goals, respectively; 22.1

231 ic method for direct detection of hemoglobin A1c (Hb(A1c)), a potent biomarker for diabetes diagnosis

232 dual detection and measurement of hemoglobin A1c (HbA1c) and total hemoglobin in the whole blood (wit

233 study is to evaluate the value of hemoglobin A1c (HbA1c) as a screening tool for ketosis in T2DM pati

234 Measurement of hemoglobin A1c (HbA1c) provides an estimate of mean blood sugar lev

235 the interview or measurements of hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), and 2-hour pl

236 lysis for the glycemic outcome of hemoglobin A1c (HbA1c).

237 used to assess concentrations of hemoglobin A1c and C-reactive protein.

238 ofiling, including measurement of hemoglobin A1c and lipid levels and carotid ultrasonography.

239 Measurement of hemoglobin A1c at admission can prospectively identify a population

240 m effect on secondary outcomes of hemoglobin A1c levels, depression, or the Risk Perceptions and Risk

241 benefits (measured by lowering of hemoglobin A1c) or adverse effects?

242 , individuals with high levels of hemoglobin A1c, and those with longer duration of diabetes.

243 t metformin had similar levels of hemoglobin A1c, cholesterol, and blood pressure.

244 We measured plasma levels of hemoglobin A1c, glucose, insulin, glucagon, adipocytokines, and T-h

245 included intermediate outcomes of hemoglobin A1c, weight, systolic blood pressure, and heart rate; al

246 They had a favorable effect on hemoglobin A1c level (mean difference vs. placebo, -0.66% [95% CI,

247 rediabetes was estimated based on hemoglobin A1c measurements.

248 safety and beneficial effects on hemoglobin A1c, weight, and cardiovascular mortality (compared with

249 DM medication, a DM diagnosis, or hemoglobin A1c >= 6.5%.

250 vary with glycated hemoglobin (or hemoglobin A1c [HbA1c]) levels is unclear.

251 0.15), and nondiabetic patients (hemoglobin A1c=5.4 +/- 0.12) undergoing coronary artery bypass graf

252 trolled type 2 diabetic patients (hemoglobin A1c=6.5 +/- 0.15), and nondiabetic patients (hemoglobin

253 trolled type 2 diabetic patients (hemoglobin A1c=9.6 +/- 0.25), controlled type 2 diabetic patients (

254 etes, 1268 (34%) had prediabetes (hemoglobin A1c [HbA1c] 5.7-6.4%), and 606 (16%) had normoglycemia (

255 investigate whether preoperative hemoglobin A1c (HbA1c) levels could predict cardiovascular events o

256 Whether preoperative hemoglobin A1c (HbA1c) or postoperative glucose levels are more use

257 Preoperative hemoglobin A1c was not significantly associated with mortality or a

258 weight, body fat, blood pressure, hemoglobin A1c, fasting glucose, fasting insulin, and lipids at 3 m

259 (OR = 1.49; CI, 1.28-1.74), prior hemoglobin A1c test (OR = 1.45; CI, 1.28-1.64), and having a usual

260 h-sensitivity C-reactive protein, hemoglobin A1c, HDL cholesterol, LDL cholesterol, and triglycerides

261 ood pressure, waist to hip ratio, hemoglobin A1c level, and the ratio of apolipoprotein B to apolipop

262 nied with a subsequently recorded hemoglobin A1c level<6.0%).

263 ose tolerance (P < 0.01), reduced hemoglobin A1c levels (P = 0.01), and improved insulin sensitivity

264 Empagliflozin reduced hemoglobin A1c significantly in both groups, despite lower insulin

265 ith type 1 diabetes and screening hemoglobin A1c (HbA1c) of 7.5% to 10.9%.

266 The mean (SD) hemoglobin A1c level was 7.8% (2.4%) (to convert to proportion of t

267 s, myocardial infarction, stroke, hemoglobin A1c (HbA1C) level, treatment failure (rescue treatment o

268 cholesterol, triglycerides (TGs), hemoglobin A1c (HbA1c), and homeostasis model assessment of insulin

269 iometric method for measuring the hemoglobin A1c (HbA1c, glycated hemoglobin) concentration, hemoglob

270 ozin, even though, by design, the hemoglobin A1c difference between the randomized groups was margina

271 ence of total diabetes (using the hemoglobin A1c or FPG definition) increased from 9.8% (95% CI, 8.9%

272 ence of total diabetes (using the hemoglobin A1c or FPG definition) was 12.3% (95% CI, 10.8%-14.1%);

273 The hemoglobin A1c target for most patients with type 2 diabetes is 7%

274 ence of total diabetes (using the hemoglobin A1c, FPG, or 2-hour PG definition) was higher among non-

275 unadjusted prevalence (using the hemoglobin A1c, FPG, or 2-hour PG definitions for diabetes and pred

276 after ICU admission and underwent hemoglobin A1c testing and an oral glucose tolerance test.

277 rate, and DCCT/EDIC mean updated hemoglobin A1c (HbA1c) (2-step progression: HR, 1.28; 95% CI, 1.03-

278 gender, laterality, insulin use, hemoglobin A1c, creatinine, blood urea nitrogen, and estimated glom

279 elated with DM-related variables (hemoglobin A1c [HbA1c] and fasting glucose) at baseline and with 6-

280 between baseline and time-varying hemoglobin A1c (HbA1c) values and development of community antiinfe

281 e effect of lorcaserin on weight, hemoglobin A1c, and systolic blood pressure was consistent regardle

282 sive and standard treatment were: hemoglobin A1c <6.0% and 7.0% to 7.9%, respectively, and in the blo

283 A1c (P <= 0.001) among those with hemoglobin A1c data.

284 Among patients with hemoglobin A1c greater than or equal to 8.0% treated in the second

285 sed; however, among patients with hemoglobin A1c greater than or equal to 8.0%, the opposite relation

286 6.5-7.9% but not among those with hemoglobin A1c greater than or equal to 8.0%.

287 between FA of the left ALIC with hemoglobin A1c in diabetic subjects (DC+DD; P=.016).

288 her mortality among patients with hemoglobin A1c less than 6.5% (p < 0.0001 for each).

289 her mortality among patients with hemoglobin A1c less than 6.5% and 6.5-7.9% but not among those with

290 Among patients with hemoglobin A1c less than 6.5%, mortality increased as mean glycemia

291 ortality only among patients with hemoglobin A1c less than 6.5%.

292 r 110-160 mg/dL for patients with hemoglobin A1c less than 7% or greater than or equal to 7% (n = 3,9

293 exception of interleukin 22) with hemoglobin A1c levels.

294 ified risk factor control in YOD (hemoglobin A1c level <6.2%, systolic blood pressure <120 mm Hg, low

295 controlled risk factors at 1 year, including A1c, affects survival in patients with DM and SIHD.

296 ars; mean BMI was 25.4 +/- 5.2 kg/m(2); mean A1c was 6.5% +/- 1.1%; insulin use was 0.31 +/- 0.22 uni

297 e periodontal disease improved significantly A1c levels but did not result in a statistically signifi

298 rs with A1c <7.5%; and aged >/=19 years with A1c <7.0%.

299 ars with A1c <8.0%; aged 12 to 18 years with A1c <7.5%; and aged >/=19 years with A1c <7.0%.

300 ears with A1c <8.5%; aged 7 to 11 years with A1c <8.0%; aged 12 to 18 years with A1c <7.5%; and aged

301 led if individuals were aged </=6 years with A1c <8.5%; aged 7 to 11 years with A1c <8.0%; aged 12 to